Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Gwise TE"'
Autor:
Pulte D; Division of Hematologic Malignancies I, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD. Electronic address: Elizabeth.pulte@fda.hhs.gov., Fernandes L; Division of Biometrics IX, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD., Wei G; Division of Biometrics IX, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD., Woods A; Division of Hematologic Malignancies I, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD., Norsworthy KJ; Division of Hematologic Malignancies I, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD., Gormley N; Division of Hematologic Malignancies II, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD., Kanapuru B; Division of Hematologic Malignancies II, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD., Gwise TE; Division of Biometrics IX, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD., Pazdur R; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD., Schneider J; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD., Theoret MR; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD., Fashoyin-Aje LA; Division of Oncology III, Center for Drug Evaluation and Research, and Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD., de Claro RA; Division of Hematologic Malignancies I, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD.
Publikováno v:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2023 Jun; Vol. 23 (6), pp. 463-470.e1. Date of Electronic Publication: 2023 Mar 30.
Autor:
Norsworthy KJ; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Gao X; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Ko CW; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Pulte ED; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Zhou J; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Gong Y; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Shen YL; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Vallejo J; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Gwise TE; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Sridhara R; Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD., Deisseroth AB; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Farrell AT; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., de Claro RA; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Blumenthal GM; Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD., Pazdur R; Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Mar 10; Vol. 40 (8), pp. 847-854. Date of Electronic Publication: 2021 Dec 10.
Autor:
Nie L; Division of Biometrics IV, OB/OTS/CDER/FDA, Silver Spring, MD, 20993-0002, USA. lei.nie@fda.hhs.gov., Przepiorka D; Division of Hematology Products, OHOP/OCE/FDA, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA., Deisseroth A; Division of Hematology Products, OHOP/OCE/FDA, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA., Sridhara R; Division of Biometrics IV, OB/OTS/CDER/FDA, Silver Spring, MD, 20993-0002, USA., Gwise TE; Division of Biometrics IV, OB/OTS/CDER/FDA, Silver Spring, MD, 20993-0002, USA.
Publikováno v:
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2018 Aug; Vol. 32 (4), pp. 325-330.